<DOC>
	<DOCNO>NCT03088839</DOCNO>
	<brief_summary>Amyotrophic Lateral Sclerosis ( ALS ) rare disease worldwide incidence 2-3 case per 100,000 individuals/year characterize progressive neurodegeneration motor neuron . When motor neuron degenerate ability brain initiate control muscle movement lose . ALS manifest two form : Familiar ALS ( FALS ) inherit risk genotype , account 10 % case sporadic ALS ( SALS ) without apparent heritability account 90 % case . ALS occur female male subject age common people age 40 . Although molecular mechanism underlie pathogenesis ALS still investigation , recent research reveal disease affect motor neuron may associate alteration RNA metabolism biogenesis small non-coding micro RNAs ( miRNAs ) . miRNAs circulate molecule , whose expression profile widely describe important potential monitoring progression disease , promote development target therapy and/or determine effectiveness treatment . Altered pattern specific miRNAs expression describe several pathological condition . Evidence show significant reduction level certain miRNAs also patient ALS . Among others , miRNA-218 describe play critical role onset motor neuron differentiation establish cell identity fate . Changes level miRNA-218 serum ALS patient may potentially provide useful tool determine possible association disease candidate indicator disease progression .</brief_summary>
	<brief_title>Circulating Biomarker Amyotrophic Lateral Sclerosis ( ALS )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>ALS patient admit Centre Rare Diseases , IRCCS Neuromed , Patients diagnose ALS within 6 month , Patients age 20 year 75 year old , Patients underwent differential diagnosis use diagnostic tool ( EMG , NCV , MRI ) exclude disease similar sign symptom , Subjects able communicate verbally use nonverbal communication system . Pregnant woman , Subjects malignant tumor , Subjects/Patients others neurological psychiatric disorder , Subjects/Patients systemic disease , Subjects/Patients positive blood test hepatitis B C , HIV , Patients include clinical trial , Subjects/Patients show inability understand inform consent study 's purpose</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>